Cell Grand Clinic wins APAC regenerative medicine honor

Cell Grand Clinic in Osaka was named Top Regenerative Medicine Solution Provider in APAC 2026 by Healthcare Business Review APAC. The recognition highlights the clinic’s government-certified autologous stem cell therapy model, 13 approved treatment plans and international patient base.

Why it matters: - Cell Grand Clinic’s award signals growing regional recognition for Japan-based regenerative medicine providers. - The clinic’s model centers on patient-specific therapy using a patient’s own adipose-derived stem cells, which is meant to reduce donor matching and standardize care within Japan’s regulatory system. - The recognition may matter to international patients seeking certified treatment options in Osaka.

What happened: - Healthcare Business Review APAC named Cell Grand Clinic Top Regenerative Medicine Solution Provider in APAC 2026. - The publication placed Cell Grand Clinic among its top 10 regenerative medicine providers in the region. - The clinic is based in Osaka and serves international patients from about 20 countries. - Dr. Yuichi Wakabayashi founded the clinic in 2025.

The details: - Cell Grand Clinic operates 13 treatment plans certified by Japan’s Ministry of Health, Labour and Welfare. - The certified plans cover knee osteoarthritis, type 1 and type 2 diabetes, arteriosclerosis, age-related decline and anti-aging, chronic pain, and dermatologic and androgenetic applications. - The clinic provides English-language patient education on stem cell therapy for knee osteoarthritis and its other treatment areas through its resource library. - Every treatment uses the patient’s own adipose-derived cells. - The clinic does not use donor matching or batch pooling, and each culture is patient-specific. - Cell processing uses a passage 3 culture stop. - The clinic uses flow cytometry verification aligned with the International Society for Cell & Gene Therapy. - The clinic reports post-thaw viability of 95% or higher. - Outcomes depend on individual patient factors, and results vary. - The clinic’s care model keeps one physician involved from first inquiry through the six-month follow-up. - Dr. Wakabayashi says the same physician designs the protocol, performs the harvest, supervises culture, administers the cells and tracks outcomes. - Dr. Wakabayashi is certified by the American Board of Regenerative Medicine. - He was previously a research fellow at the U.S. National Institutes of Health. - He has performed more than 3,000 ADSC treatments over his career. - He also serves as a lecturer in regenerative medicine at Kindai University School of Medicine. - The award follows coverage in The Wall Street Journal and membership in Medical Excellence JAPAN. - The clinic operates in central Osaka’s Shinsaibashi-Midosuji corridor. - The facility includes private consultation and treatment rooms and a four-patient simultaneous infusion suite. - The location is near international hotels, dining and halal-friendly establishments. - The clinic supports visitors from Greater China, Southeast Asia and the Middle East, along with English-speaking patients from the Americas, Europe and Oceania. - During the multi-week culture period, the clinic offers supportive options such as exosome or PRP administration on the same day as the adipose harvest. - A 14th plan, autologous ADSC therapy for Alzheimer’s disease, is under Ministry of Health, Labour and Welfare review and is scheduled to launch in July 2026. - Dr. Wakabayashi has received both stem cell and exosome therapy himself. - He was quoted as saying he prescribes only what he is willing to undergo himself. - More information is available on Cell Grand Clinic’s website.

Between the lines: - The award, the clinic’s physician-led structure and its government-certified treatment menu position Cell Grand Clinic as a premium, regulated option in a crowded wellness and regenerative medicine market. - The emphasis on standardized processing, physician continuity and international accessibility suggests the clinic is targeting medical travelers as much as local patients. - The planned Alzheimer’s treatment could broaden the clinic’s offering if regulators approve the plan.

What’s next: - Cell Grand Clinic expects to launch its 14th treatment plan for Alzheimer’s disease in July 2026 if Ministry of Health, Labour and Welfare review is completed. - The clinic is likely to continue targeting international patients through its English-language resources, multilingual support and central Osaka location. - The clinic’s profile may rise further if its regional recognition leads to more cross-border patient interest.

The bottom line: - Cell Grand Clinic is pairing Japan’s regenerative medicine regulation with a physician-led, patient-specific stem cell model to attract international patients and stand out in APAC.